// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

A global survey of the use and linguistic translation of the NMSQuest and NMSScale: implications for non-motor studies in Parkinson’s disease

A. Sauerbier - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

A long-term study on effectiveness of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients

K.R. Chaudhuri - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Carbidopa and Levodopa

A new neurophysiological tool for differential diagnosis in tremor syndromes: The Tremor Stability Index

L. di Biase - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A new psychosocial intervention for people with Parkinsonian dementias: Adherence, barriers and facilitators

S. McCormick - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A qualitative study of the views and experience of people with Parkinson’s disease regarding their footwear

A. Ashburn - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

A randomised control trial to investigate if people with Parkinson’s disease can exercise at high intensity, and does this improve their cardiorespiratory function? A feasibility study

M. Harvey - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

A Service Evaluation of the Clinical Use of Parkinson’s KinetiGraph (PKG) Movement Recording System in the Assessment of Parkinson’s Disease Patients with Tremor

J. Price - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Altered PDE10A Expression Detectable Early in Untreated Parkinson’s Disease Patients

G. Pagano - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Anatomical predictors of survival in PSP: thalamic collapse towards the end of life

W. Bevan-Jones - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Are patients with Parkinson’s disease who have either mild to moderate microsmia, severe microsmia or anosmia clinically different?

c. cox - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Are there genotype-phenotype correlations in Perrys syndrome?

J. Panicker - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Aspects of Quality of Life in MSA and PSP

L. Wiblin - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessing Bone Health in Parkinson’s – When and how?

A. Dzharif - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Assessing Nigral Functional Connectivity in Parkinson’s Disease with Resting State Functional MRI

A. Martin-Bastida - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Assessing Parkinson’s disease motor symptoms using supervised learning algorithms

P. Angeles - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Assessing the extent of carer strain in Parkinson’s disease

R. Varadarassou - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Associations of DAT SPECT and TCS with prodromal features of Parkinson’s disease: results in PREDICT-PD participants

A. Noyce - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Congenital disorder

Parkinson's disease

N/A

Barriers to exercise in newly diagnosed Parkinson’s disease

I. Argyropoulos - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Can the level of CSF Neurofilament Light Chain predict disease progression in Progressive Supranuclear Palsy?

E. Jabbari - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Progressive supranuclear palsy

N/A

Changing patterns of intimate relationships as dementia emerges in Parkinson’s disease

S. Vatter - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Copyright © 2026. QuantiNova All rights reserved